by Lupus Foundation, Ohio | Jan 30, 2026 | Lupus Foundation of America, News & Events
The U.S. Food and Drug Administration (FDA) has granted Biogen’s investigational drug, litifilimab, Breakthrough Therapy Designation for the treatment of cutaneous lupus erythematosus (CLE, a chronic autoimmune skin disease). This designation is given only to...
by Lupus Foundation, Ohio | Jan 15, 2026 | Lupus Foundation of America, News & Events
In a new study, researchers examined herbal supplements with immune-activating properties that could trigger or worsen autoimmune skin conditions, such as in people with cutaneous lupus erythematosus (CLE) or systemic lupus erythematosus (SLE). They identified 227...
by Lupus Foundation, Ohio | Jan 11, 2026 | Lupus Foundation of America, News & Events
AstraZeneca reported positive results from a Phase III TULIP-SC clinical trial, showing a statistically significant and clinically meaningful reduction in disease activity with the subcutaneous (SC), self-administration of Saphnelo (anifrolumab) in adults with...
by Lupus Foundation, Ohio | Jan 9, 2026 | Lupus Foundation of America, News & Events
Johnson & Johnson announced positive topline results from its Phase 2 randomized placebo-controlled JASMINE study. The drug therapy, nipocalimab, met its primary endpoint and multiple key secondary and exploratory endpoints in adults with systemic lupus...
by | Dec 18, 2025 | Lupus Foundation of America, News & Events
A new study finds that experiences of discrimination are associated with worse patient-reported lupus-related symptoms and depressive symptoms among people with systemic lupus erythematosus (SLE). Patient-reported disease activity such as pain, fatigue and depression...
by | Dec 16, 2025 | Lupus Foundation of America, News & Events
In a new study, researchers have discovered a connection between inflammation in the areas of interstitial fibrosis and tubular atrophy (IFTA), a common pattern of kidney damage often seen in kidney disease, and renal outcomes. The researchers found that inflammation...
